Statements (102)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Genetics
|
| gptkbp:acquisition |
gptkb:Archer_DX
gptkb:Gene_Dx gptkb:J._Craig_Venter_Institute gptkb:Sema4 |
| gptkbp:awards |
recognized for innovation
|
| gptkbp:ceo |
Sean George
|
| gptkbp:clinical_trial |
ongoing
|
| gptkbp:collaboration |
academic institutions
research institutions biopharmaceutical companies |
| gptkbp:collaborations |
with hospitals
|
| gptkbp:community_engagement |
patient advocacy groups
|
| gptkbp:community_outreach |
health fairs and events
|
| gptkbp:competitors |
gptkb:Gene_Dx
gptkb:Myriad_Genetics gptkb:23and_Me gptkb:Color_Genomics Ambry Genetics |
| gptkbp:customer_base |
healthcare providers
pharmaceutical companies research institutions patients patients and healthcare providers |
| gptkbp:customer_support |
available for inquiries
|
| gptkbp:data_privacy |
GDPR compliant
HIPAA compliant |
| gptkbp:educational_resources |
available online
|
| gptkbp:employees |
over 1000
over 1,000 |
| gptkbp:financial_support |
financial assistance programs
|
| gptkbp:focus |
healthcare
|
| gptkbp:founded |
gptkb:2010
|
| gptkbp:founder |
Sean George
|
| gptkbp:funding |
gptkb:venture_capital
public offerings private placements |
| gptkbp:future_plans |
increase accessibility
enhance technology expand test offerings |
| gptkbp:genetic_counselors |
available for consultations
|
| gptkbp:genetic_testing_impact |
improves patient outcomes
|
| gptkbp:genetic_testing_trends |
increasing demand
|
| gptkbp:genetic_variants |
classified by clinical significance
|
| gptkbp:global_presence |
available in multiple countries
|
| gptkbp:headquarters |
gptkb:San_Francisco,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Invitae
|
| gptkbp:is_tested_for |
diagnostic testing
actionable insights pharmacogenomics carrier screening predictive testing |
| gptkbp:market_position |
leading genetic testing company
leading genetic testing provider |
| gptkbp:mission |
to bring comprehensive genetic information into mainstream medicine.
to bring comprehensive genetic information to mainstream medicine |
| gptkbp:partnership |
gptkb:Mayo_Clinic
gptkb:Cleveland_Clinic gptkb:Quest_Diagnostics gptkb:Lab_Corp academic institutions pharmaceutical companies various healthcare providers |
| gptkbp:product |
Invitae Cardiomyopathy Panel
Invitae Carrier Screen Invitae Epilepsy Panel Invitae Genetic Health Screen Invitae Hereditary Cancer Test Invitae Neurology Panel Invitae Pediatric Panel Invitae Pharmacogenomics Panel Invitae Prenatal Screen |
| gptkbp:provides_guidance_on |
followed in testing
|
| gptkbp:provides_information_on |
with consent
|
| gptkbp:publication |
peer-reviewed journals
|
| gptkbp:regulatory_compliance |
gptkb:CLIA
gptkb:FDA CAP CLIA certified CAP accredited |
| gptkbp:research_focus |
genetic disorders
rare diseases neurological disorders pharmacogenomics cancer genetics cardiovascular genetics |
| gptkbp:revenue |
over $100 million
$200 million (2020) |
| gptkbp:services |
genetic testing
|
| gptkbp:stock_exchange |
gptkb:NASDAQ
|
| gptkbp:stock_symbol |
NVTA
|
| gptkbp:technology |
next-generation sequencing
|
| gptkbp:test_accuracy |
high sensitivity and specificity
|
| gptkbp:test_interpretation |
provided by experts
|
| gptkbp:test_menu |
expanding regularly
|
| gptkbp:test_pricing |
varies by test type
|
| gptkbp:test_results_confidentiality |
ensured by policies
|
| gptkbp:test_turnaround_time |
2-3 weeks
|
| gptkbp:test_volume |
increasing annually
|
| gptkbp:testimonials |
available on website
|
| gptkbp:type_of_insurance |
varies by plan
|
| gptkbp:website |
www.invitae.com
|